Research Article

Left Ventricular Ejection Fraction Is Associated with the Risk of Thrombus in the Left Atrial Appendage in Patients with Atrial Fibrillation

Table 1

Baseline characteristics of the study population.

Parameternumber of patients

Demographic data
Age768 (years, mean (SD))63.36 (10.71) [17-90]
(years)95 (12%)
 Age 65-74 (years)271 (35%)
(years)340 (44%)
BMI567 (kg/m2, mean (SD))29.46 (5.38)
Female: (%)297 (39%)
Type of procedure768:(%)
Ablation365 (47%)
Cardioversion403 (53%)
Type of AF768:(%)
AF paroxysmal287 (37%)
Clinical data:(%)
HF766240 (31%)
 NYHA I-II209 (87.1%)
 NYHA III26 (10.8%)
 NYHA IV5 (2.1%)
HT768581 (75%)
DM767179 (23%)
Stroke76852 (6.8%)
Coronary disease768506 (66%)
Biological aortic prosthesis76819 (2.5%)
CHA2DS2-VASC score768 (mean (SD))2.48 (1.53)
: (%)65 (8.6%)
: (%)154 (20%)
: (%)549 (71.4%)
HASBLED score768 (mean (SD))1.58 (0.99)
Liver abnormal function767110 (14%)
Renal abnormal function767100 (13%)
Bleeding in anamnesis76850 (6.5%)
Laboratory data (mean (SD))761
Hemoglobin (g/dl)14.10 (1.54)
Creatinine (mg/dl)1.04 (0.31)
 ml/min/1.73 m2189 (25%)
Type of anticoagulation therapy768:(%)
NOAC523 (68%)
(i) Dabigatran240 (46%)
(ii) Rivaroxaban279 (53%)
(iii) Apixaban4 (0.7%)
VKA227 (30%)
OAC750 (98%)
Reduced NOAC54 (7%)
Heparin11 (1.5%)

Abbreviations: AF: atrial fibrillation; BMI: body mass index; DM: diabetes mellitus; eGFR: estimated glomerular filtration rate; HF: heart failure; HT: hypertension; NOAC: non-vitamin K antagonist oral anticoagulants; OAC: oral anticoagulation therapy; VKA: vitamin K antagonist.